

Analyst

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Chip Based Single Cell Analysis for Nanotoxicity Assessment

Pratikkumar Shah¹, Ajeet Kaushik², Xuena Zhu¹, Chengxiao Zhang³, Chen-Zhong Li^{1*}

¹ Department of Biomedical Engineering, Florida International University, Miami, FL, USA

² Department of Electrical and Computer Engineering, Florida International University, Miami, FL, USA

³ Key Laboratory of Applied Surface and Colloid Chemistry, Ministry of Education, School of Chemistry and Chemical Engineering, Shaanxi Normal University, Xi'an 710062, China

*Author for correspondence: Chen-zhong Li, email: licz@fiu.edu

Abstract

Nanomaterials, because of their tunable properties and performances, have been utilized extensively in everyday life related consumable products and technology. On exposure, beyond physiological range, nanomaterials cause health risks via affecting the function of organisms, genomic systems, and even central nervous system. Thus, new analytical approaches for nanotoxicity assessment to verify the feasibility of nanomaterials for future use are in demand. The conventional analytical techniques, such as spectrophotometric assay-based techniques usually require a lengthy and time-consuming process and many times produces false positives, and many times cannot be implemented at a single cell level measurement for studying cell behavior without interference of their surrounding environment. Hence, there is demand of a precise, accurate, sensitive assessment for toxicity using single cell. Recently, due to advantages of automation of fluids and minimization of human error, the integration of cell-on-a-chip (CoC) with microfluidic system is in practice for nanotoxicity assessments. This review explains nanotoxicity and assessment approaches with advantages/limitations and new approaches to overcome the confines of traditional techniques. Recent advances in nanotoxicity assessment using CoC integrated with microfluidic system are also discussed in this review, which may be of use for nanotoxicity assessment and diagnostics.

Keywords: *Nanotoxicity, Nanobiotechnology, Electrochemical techniques, Single cell-on-a-chip*

1 Nanotoxicity

Nanotechnology has been one of the hot topics in not only research but also the consumer market in last 20 years. The ongoing trend and success suggest an ever-increasing use of the nanotechnology in every sector. At the nano-scale, nanomaterials/nanoparticles (NP ~1-50 nm) demonstrate unique physico-chemical properties in comparison to their bulk form. The unique features, such as size, shape, surface properties, etc., have inspired the production of nanomaterials not only at the research level, but also at the industrial scale for various applications. NPs are increasingly exploited in cosmetics, food, electronics, paint, material science, medicine, biotechnology, and energy technologies. The Nanotechnology Consumer Products Inventory list currently contains 1628 consumer products (not comprehensive), a 24% increase from the 2010 update ¹ and maybe thousands of nanomaterials are handled at research level without knowing proper details about them. With increased production and use of nanomaterials lies the risk of increased intentional/unintentional exposure to these particles ²⁻⁴.





Figure 1: Schematic of NP localization in various body organs (Figure is reused with permission from reference ⁵).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Despite the NPs positive properties, they do have adverse effects on human, animals and environment living due to their own toxicity. NP toxicity has been studied and assessed for years; however it lacks any gold standard techniques due to several limitations. First and foremost, even the toxicity of nanoparticles does not have a common agreement ⁶. Some limitations are due to the lack of understating of the NPs potential interaction with biological systems ^{7,8} and there are no specific tools which can provide rapid nanotoxicity assessment.

NPs with many novel properties are used in various applications and come in interaction with complex and dynamic biological systems. It is challenging to characterize NPs throughout their biological interaction and to quantify the uptake rate and localization inside the body parts and cells. Cells under nanotoxicity may undergo necrosis or repairable oxidative DNA damage and recover from it eventually, or may result in apoptosis. Nanotoxicity may alter cell differentiation, proliferation, morphology, or cell-cell communication. Upon exposure, NPs can enter into human body by either inhalation, ingestion, injection or through skin contact. NPs can localize into different organ and tissues and further induce organ targeted toxicity/disease. Figure 1 highlights the possible accumulation of NPs in various organs. Some NPs can cross blood-brain barrier (BBB) ⁹ (Figure 2-a ¹⁰) and hence have been proposed for diagnostic and therapeutic applications ^{11,12}. Their smaller size and larger surface area provides NPs' unique properties in their translocation to the systemic circulation and CNS. Once inhaled, nanoparticles can pass through epithelia of respiratory track and access the bloodstream directly or via lymphatic pathways ^{13,14}. NPs also can be translocated in the CNS by nerve endings embedded in airway epithelia and nerve endings of the olfactory bulb ^{13,15}. NPs can damage cells by reactive oxygen species (ROS) formation, mechanical damage of intracellular organelles, and an imbalance in cytosolic Ca²⁺ concentration ¹⁶⁻¹⁸ (Figure 2-b). NPs' hostility on ion channels and synapse, important components in neuron communication, cannot be denied. Usually, neurodegenerative diseases such as Alzheimer, Parkinson, Huntington's disease, etc., are

1
2 diagnosed at a much matured stage and very narrow success has been achieved to improve the
3
4 patients' conditions. To understand the role of the NPs interaction with neurons is critical to
5
6 sense any dis-functionality in cell behavior.
7
8



46 Figure 2: (a) Illustration of possible pathways in which NPs can cross blood brain barrier. The pathway
47 depends on the material and size of NPs. (b) Illustration of cell-NP interaction and nanotoxicity
48 generation. Event 1 represents the extracellular ROS generation outside and inside the cell. Event 2
49 represents the damage to the cell membrane integrity. Event 3 is particle dissolution or ion leaching
50 affecting the cell function. Event 4 signifies mechanical damage to intracellular organelles due to NP
51 intrusion. Event 5 is indicating the role of NP surface properties (roughness, charge, and active groups)
52 whereas event 6 is highlighting the role of NP size in toxic effects to a cell. Event 7 is representing the NP
53 shape induced toxicity as different shapes of NP may interact with the cell differently. Event 8 is
54 dissolution or leaching of nanoparticle outside the cell membrane and making it easier to penetrate the
55 cell membrane for nanoparticle and affect the cell function. Figures 2-a and 2-b are reused with
56 permission from references ¹⁰ and ¹⁶, respectively.
57
58
59
60


1
2 Research about the potential health risks of NPs exposure lags behind the rapid
3 development of nanotechnology¹⁹⁻²². Only the federal agency of United States alone has
4 invested \$750 million (from 2006-2014) in research to establish “risk assessment” of
5 environment health and issues related to use of nanomaterials²³. The National Institute for
6 Occupational Safety and Health (NIOSH) has identified risk assessment as one of the 10 critical
7 areas that it wants to “guide in addressing knowledge gaps, developing strategies, and providing
8 recommendations”²⁴. Strategic efforts of US and Europe are continuing to establish risk
9 assessment of nanoparticle exposure. The silent features of a NP which cause toxicity are
10 discussed on next section.

11 **1.1 Causes of nanotoxicity**

12
13 The physico-chemical properties of materials play an important role when NPs interact with
14 biomolecules or biological systems. These properties not only define the uptake and excretion of
15 NPs, but also explain the interference (toxicity) with the biological system²⁵. The most discussed
16 properties of a NP causing toxicity are its chemical composition, shape, size, surface charge,
17 surface functional group, reactivity, and ability of a material to be stable in the biological system
18 (Figure 3). Also, the longevity of NP-cell interaction and the exposed dose are definitely
19 deciding factors in the adverse effects of nanomaterials.

20
21 The intrinsic property (chemical composition) of a material defines the basic character of a
22 material. For that reason, some nanomaterials (e.g., CdO, CuO) are toxic whereas some materials
23 are biocompatible (less or non-toxic, e.g., Au, FeO₃)²⁶. In an experiment performed by our
24 group earlier, we found that gold NPs are nontoxic while cadmium oxide nanoparticles of the
25 same size and dose are highly toxic, whereas Ag and CNT showed some sign of toxicity²⁷.
26 Shape and size of a NP becomes an important factor to provide large surface to volume ratio to
27 the nanoparticles. It is generally believed that the smaller the NP, more toxic it is²⁸. Due to
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 larger surface to volume ratio, NPs have more molecules on the surface and possess higher
3 reactivity which can enhance the intrinsic toxicity²⁹. In a recent study by Wang et al., it was
4 found that longer single wall carbon nanotubes were more toxic than short single wall carbon
5 nanotubes on PC12 cells³⁰. Another study conducted by Napierska et al.³¹ showed that the
6 mono-dispersed amorphous silica NPs exhibit size dependent toxicity on endothelial cells with
7 smaller size of NPs of the same morphology being highly toxic compared to larger size of NPs at
8 same concentration. The surface properties of a NP play a great role in defining its reactivity in
9 biological systems. Sometimes, the toxicity of NPs can also be tuned by changing its surface
10 property, such as by decorating a compatible functional group or by changing the surface charge
11 (zeta potential). Huang et al. showed that the shape of the mesoporous silica NP affect the
12 cellular functions³². A study conducted by Marques et al.³³ to verify the surface charge effect on
13 internalizations of noble NPs, Au (~26.5 nm) and Ag (~33.3 nm), showed that the positively
14 charged NPs (Au⁺ and Ag⁺) were more susceptible to internalization by the mast cells compared
15 to their negatively charged counterparts (Au⁻ and Ag⁻).




56
57 Figure 3: Illustration of NPs basic properties responsible for toxicity. (a) Illustration of the size effect of
58 NP, smaller NPs (<5 nm) not only can cross the cell membrane, but also can interfere and damage the
59
60

intracellular organelles. (b) Illustration of different shape of nanomaterials; it is proven that a sphere shape NP is less toxic than a rod or star shape NP. (c) Illustration of NP surface functionalization; besides the intrinsic surface property i.e. surface roughness and surface charge, the functionalized group on the surface plays a major role in dictating the behavior of NP in biological system.

1.2 Single cell nanotoxicity measurement

Traditional methods of analyzing cells are based on the averaging of results studied from multiple cells in an assay, also referred as bulk assay. The results are correlated and assumed to be equally contributed to by all cells of the population under study. However, recent advancements in single cell studies have shown that individual cells behave differently from the population even under identical environmental conditions.



mRNA expression of GAPDH from individual Jurkat cells

Figure 4: Gene expression of GAPDH for Jurkat cells treated with GAPDH siRNA relative to normal untreated cells. The levels of GAPDH expression roughly fall into two categories: 0% and 50% of normally untreated cells. However, the average GAPDH expression from bulk assay (50 cells) is $21 \pm 4\%$, which is not representative of any individual cell. Figure adapted from ³⁴.

Cell heterogeneity has been studied by researchers recently, suggesting that the cells in a sub-population may have different behavior from the general population results ³⁵⁻³⁷. In a published study by Toriello et al. ³⁴ (Figure 4), mRNA expression of GAPDH from individual

1
2 Jurkat cells after siRNA knockdown, the levels fall into roughly two categories: 50% and 100%
3
4 knockdowns (i.e. 50% and 0% expression remained). Importantly, the average GAPDH
5
6 expression obtained from the measurement of 50 cells ($21 \pm 4\%$) was not representative of any
7
8 individual cell. This means that the cell population study in aggregation may hinder some very
9
10 important cell mechanisms which are only visible at the single cell level. To study the true
11
12 functionality of a cell, it is really important to study a cell independently without interference
13
14 from neighboring cells. Studying multiple cells in a single assay might obscure some important
15
16 information that can only be understood by a single cell study. In bulk assays, the difficulties to
17
18 distinguish the result from a smaller response of homogeneous population or a larger response
19
20 from a small subpopulation of cells have been discussed earlier ³⁸. Therefore, single cell analysis
21
22 can be an equivalent and complementary strategy to existing approaches. Especially for neuronal
23
24 cells, the physiological function can be monitored by recording the pattern of electrical activity
25
26 and any disturbance in these patterns of electrical activity could serve as a highly sensitive way
27
28 to measure the functional toxicity as interference of the functional activity can be observed
29
30 before any other changes are monitored, and much before the cell death. Figure 5 illustrates the
31
32 reasons of the selection of the single cell for nanotoxicity assessment.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

WHY SINGLE CELL ?




Figure 5: Highlights of the single cell study. Single cell behavior differs due to heterogeneity, which is a resultant of one of the genetic, biochemical/metabolic, physiological or behavioral heterogeneity. Additional benefits such as observation of discrete and dynamic events of cell during cell's life-time, cellular pathways study without interference of neighbor cells, comparison or relating microscopic to macroscopic (single cell to a large population of cell) and study or rare and transient cell states can only be achieved by single cell analysis.

2. Assessment of nanotoxicity: *state-of-the-art*

Since, various characteristics or properties of a NP can induce toxicity in a numerous ways; many toxicity assays from chemical toxicity assays are available for toxicity assessment. Principally, the toxicity of NPs is measured in terms of change in viability of cells or functional changes in the cells (i.e. DNA damage, gene alteration, ROS generation). The detailed explanation of conventional nanotoxicity assessment techniques have been explained in many reports^{39, 40}. Figure 6 illustrates the adopted strategies for nanotoxicity assessment. The brief introduction and state-of-the-art features of these techniques are described in the next section.

MTT, LDH, and Spectrophotometric Assays

- Measure the activity of enzyme in living cell
- Not possible at single cell level
- Final time point measurement
- Many times require cell lysing
- Mostly, labeling required
- Time consuming and costly
- Specificity and sensitivity can be argued

Electrochemical Assays

Impedance Spectroscopic Assessment

- Real time kinetics of the nanoparticle interaction with the cells
- Can not provide information about cell signaling at single exocytosis/vesicle resolution

Amperometric Assessment

- Sensitive and provide cell signaling kinetics information at single exocytosis/vesicle level
- Complex setup and require a trained personnel.

Figure 6: Table highlighting the common limitations associated with dye/optical based assay and electrochemical approach as an alternative mechanism for nanotoxicity assessment.

2.1. Viability assays

Metabolic rate, cellular membrane integrity, apoptotic/necrotic cell death or the rate of proliferation properties of cells is utilized to evaluate cell viability. The parameters may overlap and is presented only as a classical way of cell viability demonstration. Dye based viability assays mostly work on the principle of inclusion, exclusion or conversion of an added dye in live versus dead cells which can further be identified by colorimetric or fluorescent assays⁴¹. Trypan blue exclusion assay⁴¹⁻⁴⁴ is used to characterize the viability of cells. This assay is based on a diazo dye, which can only be taken up by dead cells and is excluded by live cells. Alamar Blue assay^{41, 43, 45} is another common cell viability assay. The Alamar Blue reagent is a non-toxic,

1 water-soluble resazurin dye that yields a fluorescent signal and a colorimetric change when
2 incubated with metabolically active cells. There are many other dye based (fluorescent and non-
3 fluorescent) live-dead assays, such as calcein AM and propidium iodide based assays ⁴⁶, neutral
4 fluorescent) live-dead assays, such as calcein AM and propidium iodide based assays ⁴⁶, neutral
5 red assay ⁴⁷, and Live/Dead (Invitrogen, Carlsbad, CA) ⁴⁸.
6
7
8
9

10
11 LDH (Lactate dehydrogenase) assay ^{31, 41, 49, 50} has been used to understand the integrity of
12 cellular membrane. LDH is an indicator of lytic cell death, as soluble LDH is released into the
13 extracellular medium through damaged cell membrane. Tetrazolium salt-based assays (MTT,
14 MTS, WST) ^{49, 51, 52} are widely used for the proliferation rate measurement of cells under the
15 influence of NPs. In this metabolic assay, MTT is reduced by cells into blue/purple color non
16 soluble formazan dye. Formazan dye is then solubilized in DMSO to get the average idea of cell
17 viability. Higher metabolic rate (more blue color) is an indication of more viable cells in the
18 population. In a ³H Thymidin-based assay ⁵³, uptake of ³H by newly synthesized DNA can be
19 used as the detection of cell proliferation. Alamar Blue is comparatively simpler and more
20 sensitive method for cell metabolism detection than MTT; however, possibilities of false
21 positives or negatives cannot be nullified ⁵⁴. A study conducted by Riviere and Zhang ⁵⁵ showed
22 that the obtained results of viability with different dyes for different materials were inconsistent
23 and this inconsistency could be contributed by nanomaterial/dye interaction and nanomaterial
24 adsorption of the dye. Thus, it is always recommended to use more than one type of dye-based
25 assays before confirm the results. Casey et al. ⁵⁶ found that the CNT interfering with MTT,
26 Alamar Blue and neutral red dyes giving false measurements and so pressed the urgent need of
27 developing alternative techniques to quantify nanotoxicity. These studies raised concern about
28 widely used viability/cytotoxicity assays for nanomaterial toxicity screening and thoughtfully
29 suggested the need of alternative techniques for nanomaterial and biological system interaction
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 evaluation. This also highlights the basic limitation of the conventional and new dye-based
3
4 assays in general.
5
6

7
8 The above-mentioned assays are bulk, require a huge population of cells to experiment and a
9
10 consensus is built for every cell. Since, the role of the single cell study is found to be important,
11
12 there are a few single-cell based viability dye-based cell viability assays which can further be
13
14 incorporated with flow-cytometer for high throughput detection. Annexin V is a marker of
15
16 externalization of phosphatidylserine on the outer surface of plasma membrane, is an early sign
17
18 of apoptosis. Labeling of annexin V ⁵⁷ with fluorescent or radioactive molecules makes it
19
20 possible to identify the binding of annexin V on the surface of dead (apoptotic) cells. TUNEL
21
22 assay ⁵⁸ can be used to identify the cell death (apoptotic) by detecting fragmented DNA by
23
24 labeling the terminal end of nucleic acids. Colony forming assay ⁵⁹ does not require any
25
26 additional tagging. Here, the ability of a single (or very few cells) to form a colony is measured
27
28 as indication of being healthy over the period of few days.
29
30
31
32

33 34 **2.2. Functional assays**

35
36
37 Functional assay are more specific to detect nanotoxicity at the genomic level, change in
38
39 gene formation, DNA damage, reactive oxygen species (ROS) generation, etc.
40
41

42
43 Oxidative stress is commonly observed due to the influence of NPs ^{41, 57}. This phenomenon is
44
45 linked with toxicity as un-repairable oxidative stress generates free intra-cellular radicals and
46
47 damages the lipid, protein, and nucleic acids. Direct/indirect intracellular ROS measurement
48
49 assays include the glutathione (GSH) assay ⁶⁰, which is a luminescent-based assay and has been
50
51 used for the detection and quantification of glutathione in cells. Lipid peroxidation measurement
52
53 assay measures increasing concentrations of end products of lipid peroxidation indicating
54
55 increased oxidative damage in the cells ^{39, 41, 42, 45, 61}. For example, 2, 7-dichlorofluorescein
56
57
58
59
60

1
2 (DCFH) assay which detects intracellular DCFH oxidation due to the presence of hydrogen
3
4 peroxides^{41, 43, 45, 47, 57, 60, 62} to measure free radicals in cells and tissue. Besides stress, cellular
5
6 inflammation response also can be used as the measure of cytotoxicity by detecting specific
7
8 biomarkers. Cytokines are particularly related with the cell proliferation and inflammation.
9
10 Immunoassays (i.e. ELISA⁶³) are used to detect secreted cytokines such as detection of
11
12 interleukin 6 (IL-6)⁶⁴, interleukin 8 (IL-8)^{64, 65} or monocyte chemotactic protein-1 (MCP-1)⁶⁶.
13
14 However, ELISA tests are usually time consuming and require multiple operations. Detection of
15
16 DNA damage can be sensed at the single cell level by comet assay (single cell gel
17
18 electrophoresis)⁶⁷. However, mitochondrial DNA damage and smaller DNA fragments (<50 Kb)
19
20 are hard to be detected by comet assay, and some apoptotic cells also that can be washed during
21
22 the lysis will not be detected by the assay. Mutation or the change in a particular gene can be
23
24 identified by several assays for oxidized guanine bases. These modifications are often the
25
26 resultant of oxidative stresses and traditionally are identified by immunohistochemistry or HPLC
27
28 techniques. PCR/RT-PCR array⁶³ can be used to identify the panel of genes. Karyotype analysis
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Traditionally, we have seen dye based assays for the nanotoxicity assessment and it has been shown that NPs interfere with dye and many times give false positive results. Moreover, many times these techniques possess limitations of being end point measurements instead of dynamic and real-time measurements, requiring cell lysing and cannot be performed on single cell level without an additional labeling system. Recent advances in nanotoxicity assessment have tried to address some of the problems faced by these traditional techniques and are discussed in the following section.

3 Recent advances in nanotoxicity assessment

The growth of nanotechnology has offered not only the nanomaterials with unique properties, but also presented advanced analytical tools which exhibit highly sensitive sensing mechanisms. Efforts have been put together to develop either device based or new technique based approaches to evaluate the hidden parameters of NP-biological interaction (Figure 7).

3.1 Lateral flow immunoassay

ROS induced oxidative DNA damage is a well-known trait of nanotoxicity. 8-hydroxyguanine and its nucleoside 8-hydroxy-2'-deoxyguanosine (8-OHdG) are the most studied oxidized guanine bases ⁶⁹. Commonly used techniques for 8-OHdG analysis are high-performance liquid chromatography (HPLC) with electrochemical detection (ECD), gas chromatography-mass spectrometry (GCMS), HPLC tandem mass spectrometry, and Enzyme linked Immunosorbent Assay (ELISA). However, most of these techniques are time-consuming, expensive, and require special techniques and equipment. Our group has recently developed a novel lateral flow immunoassay (LFIA) ⁷⁰ to overcome these challenges and to measure the concentration of 8-OHdG and thus reveal the nanotoxicity on the genomic level. The LFIA approach can be simple, scalable, and inexpensive analytical tool for nanotoxicity detection. However, cell lysing was a compulsion for this end point measurement technique.




Figure 7: Recent advancement for nanotoxicity assessment. (a) Lateral flow immune-strip (FLIS) is very common for pregnancy test and some other biomarker application. LFIS was first time used for evaluation of genotoxicity/ DNA damage detection upon NP exposure in reference ⁷⁰. (b) AFM is used to measure the adhesion force and stiffness of the cell membrane upon diesel NP exposure on human aortic endothelial cells ⁷¹. (c) Carbon fiber microelectrode is a very sensitive technique with very high temporal resolution and has been used recently to identify the change in exocytosis behavior of endocrine or immune cells upon NP exposure ⁷²⁻⁷⁴.

3.2 Atomic force microscopy

Atomic force microscopy (AFM) is a powerful force sensitive technique and has been successfully applied in single cell studies to gather the information on cell structure, topography, membrane nanostructures, and mechanics (e.g., adhesion force, elasticity) of mammalian cells at a nano-scale resolution under physiological conditions or near physiological conditions ⁷¹. In a recent study by Blechinger et al. ⁷⁵, the uptake and localization of SiO₂ NPs were scanned by using AFM combined with fluorescence microscopy. An atomic force microscope can be used to

1 study the mechanics of cell under the influence of nanoparticles. Recently, Wu et al. ⁷¹ used
2 AFM to study the biophysical properties of vascular endothelial cells at a single cell level upon
3 diesel exhaust particles exposure. By using AFM, Wu et al. measured the mechanical properties
4 (young's modulus and adhesion force) and the topography of the cell membrane.
5
6
7
8
9

10 **3.3. Carbon fiber microelectrode**

11
12 Carbon fiber microelectrodes (CFME) of tip size ~5-10 μm exhibit high sensitivity and
13 low noise levels for single cell analysis. Their ability to detect diffusion limited current at very
14 high scan rates allows better temporal resolution ⁷⁶. CFME amperometry technique is used to
15 explore biophysics of exocytosis, and has been proved as an important tool to understand cellular
16 communication under the influence of NPs. Marquis et al. ⁷⁷ used CFM amperometry to
17 characterize serotonin exocytosis from murine peritoneal mast cells co-cultured with fibroblasts
18 for 48 hours on interaction with Au nanoparticles (12-46 nm). A decrease in granule transport
19 and fusion events along with increments in intracellular matrix expansion and higher number of
20 serotonin exocytosis per granule was observed. The effect on cell viability when NP exposure
21 was extended for 48 and 72 hours ⁷⁴ was also studied. The effect of citrate reduced noble NPs,
22 Au (28 nm) and Ag (61 nm), on neuroendocrine cells has been evaluated by Love and Haynes ⁷².
23 In this work, the uptake quantification, the lysing of the cells, and the total metal content were
24 measures of NP uptake and were measured using inductively coupled plasma-atomic emission
25 spectroscopy (ICP-AES). The uptake rate for Ag and Au NPs (1 nM) was found different for
26 each type after 24 hours of exposure, 3.4×10^4 versus 7.5×10^5 NPs per cell, respectively. This
27 suggests higher internalization of the Au NPs. The observed different rate of NP internalization
28 was dependent on factors like size, surface charge, and functionalization. CFME amperometry
29 exposed the changed exocytosis behavior of chromaffin cells in this study.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 Metal oxide NPs (MONP) such as nonporous SiO₂, porous SiO₂, and nonporous TiO₂ are
3
4 being used in consumer products of everyday life. CFME amperometry technique has explored
5
6 the nanotoxicity effect of MONP on immune cells by Maurer-Jones et al.⁷³. The outcomes of
7
8 their studies revealed functional changes in chemical messenger secretion from mast cell
9
10 granules. The surface properties of NPs are known to play a major role to decide the nature of
11
12 interaction with biological systems. Love et al.⁷⁸ further utilized this technique to evaluate the
13
14 changes in cellular communication in neuroendocrine cells on exposure of size dependent Ag
15
16 NPs and surface functionalized Au NP for 24 hours. Authors conclude that Ag NPs of 15 - 60
17
18 nm do not alter cell viability but exhibited size dependent cellular uptake and increase in the
19
20 speed of exocytosis release kinetics. Beside this, PEG-functionalized Au NPs did not change the
21
22 cell viability; however, they decreased the number of molecules released from each vesicle.
23
24
25
26
27
28

29 **3.4. Fluidic based cell-on-chip (CoC) approach**

30
31 Micro-chip-based biosensors show a promising future for monitoring cellular nanotoxicity as
32
33 they allow rapid, real-time and multi-sample analysis creating a versatile, noninvasive tool that is
34
35 able to provide quantitative information with respect to alteration in cellular function under
36
37 various nanomaterials exposures. Most of the CoC-based approaches for nanotoxicity assessment
38
39 at present are based on multiple cell screening. As the importance of single cell analysis besides
40
41 the multiple cells screening already highlighted, some efforts have already been in the direction.
42
43 In a recently published study by our group⁷⁹, we presented a chip-based biosensor capable of
44
45 selective trapping of single cell dielectrophoretically in a micro-well and the same electrode can
46
47 be used for further electrochemically study the captured cell. These electrodes are independently
48
49 addressable for capturing a single cell in an individual microwell as well as study an independent
50
51 cell on order. This CoC can be used for nanomaterial based toxicity assessment. Cell behavior
52
53 can be monitored in terms of catacalomine release from cell vesicles.
54
55
56
57
58
59
60

1
2 Electrochemical and optical measurement based fluidic chip platform have been explored
3
4 for cell analysis over last decade ⁸⁰ which hold the potential to be used for nanotoxicity
5
6 assessment. Zheng et al. ⁸¹ evaluated cytotoxicity of cadmium containing quantum dots on
7
8 multicellular (HEK293 cells) events using microfluidic chip with fluorescent microscope. In
9
10 another study by Hosokawa et al. ⁸², microfluidic chip based high throughput single cell array
11
12 device was developed to study the gradient generated cytotoxic effect of toxin. Similar platform
13
14 could be applied to study nanoparticle concentration dependent toxicity in single cell. However,
15
16 optical assays are not label free and variation in batch to batch measurement due to die selection
17
18 limits the application of these assays. These challenges are being addressed using
19
20 electrochemical based nanotoxicity assessment.
21
22
23
24

25 In a recent experiment by Kim et al. ⁸³, a chip-based electrochemical approach was used
26
27 for the assessment of nanotoxicity. On a lithographically patterned chip platform, gold electrode
28
29 modified with RGD-MAP-C to enhance cell (SH-SY5Y) adhesion on the chip was used as the
30
31 sensing electrode. Silica NPs of various sizes and surface chemistries were examined to
32
33 understand the effects of induced nanotoxicity on SH-SY5Y cells by studying cell viability at
34
35 different concentrations of NPs ranging from 50 µg/ml to 400 µg/ml at various time points.
36
37 Electrochemical measurements of nanotoxicity were recorded using differential pulse
38
39 voltammetry and were compared with absorption and fluorescence-based techniques to evaluate
40
41 the benefits of electrochemical measurements to assess nanotoxicity. In another experiment to
42
43 overcome the limitation of static models, Kim et al. ⁸⁴ studied the cytotoxicity of mesoporous
44
45 silica NPs (< 50 nm) to human endothelial cells under microfluidic flow conditions to mimic
46
47 more of a blood vessel environment. This study tried to cover the missing factor of the shear-
48
49 stress component, missing in most of the *in vitro* nanotoxicity studies, to mimic the actual NP
50
51 toxicity in blood vessels. In their study, it was found that unmodified mesoporous silica NPs
52
53 induced larger loss of cell viability under shear stress conditions than static conditions whereas
54
55
56
57
58
59
60

1
2 organo-modified NPs did not have a significant difference in toxicity of both conditions. The
3
4 biggest advantage of the chip-based approach is that it provides the opportunity to measure the
5
6 real-time kinetics (dynamic) of a cell rather than only providing the end point result (static) after
7
8 a certain time, a disadvantage of major conventional nanotoxicity techniques. In a published
9
10 study by our group, Hondroulis et al. ²⁷, a whole cell based electrical impedance sensing (EIS)
11
12 approach was developed for rapid and real-time assessment of nanomaterials (gold and silver
13
14 NPs, single walled carbon nanotubes, and cadmium oxide) toxicity. This technique has huge
15
16 advantages over the traditional nanotoxicity assessment techniques. EIS is cheaper, faster, and
17
18 quantitative, and allows real time sensing of cell behavior. The study showed that gold
19
20 nanoparticles to be nontoxic and cadmium oxide to be highly toxic, whereas, smaller size of
21
22 silver nanoparticle (10 nm) were more toxic than larger (100 nm) and the length of SWCNT did
23
24 not change the toxic effects. Recently, Alexander Jr. et al. ⁸⁵ experimented silica nanowire
25
26 toxicity on epithelial breast cancer cells and found dose dependent toxicity using an array based
27
28 real-time impedance measurement chip. Impedance-based sensing approach is a highly sensitive
29
30 method to monitor cell behavior (growth, health, motion, etc.) on top of the electrode in a very
31
32 simple setup. The limitations of monolayer cell populations have also been highlighted recently
33
34 in their limitation of not being able to mimic the 3D tissue culture and emphasis on in vitro 3D
35
36 cell culture for nanotoxicity assessment. Luongo et al. ⁸⁶ recently published a study on a
37
38 microfluidic device fabrication for trapping and monitoring 3D multi-cell spheroid using real-
39
40 time electrical impedance spectroscopy (figure 8). Also the proposed designs of 3D
41
42 cellular/spheroid monitoring designs used for drug studies can be utilized for nanotoxicity
43
44 evaluation ⁸⁷⁻⁸⁹. The role of NPs for drug delivery is highlighted many times, however, a
45
46 recently published study by Albanese et al. ⁹⁰ discussed NP transport kinetics and NP tissue
47
48 accumulation in a tumor spheroid mounted on a microfluidic chip for different size, and surface
49
50
51
52
53
54
55
56
57
58
59
60

modified NPs for drug delivery and diagnostic application. Similar designs in nanotoxicity evaluation will definitely curtail the gap of nanomaterial-biological interaction.




Figure 8: A) is a microfluidic chip for spheroid capture and real-time impedimetric detection. B) is zoomed area of the microfluidic channel and the trap mechanism for spheroid. C) is the image of a multicellular spheroid before perfusion and D) is the entrapment of spheroid between two impedimetric electrodes. E) Another tumor on chip platform placed on an inverted microscope, the highlighted part is live spheroid and F) is schematic representation showing accumulation of smaller NPs (40 nm) in interstitial tissue whereas escape of bigger NPs from penetration in spheroid matrix. Images A-D are reused with permission from⁸⁶ and E-F from⁹⁰.

Looking at the recent advancements in nanotoxicity assessment, an ideal platform would look like the illustration in Figure 9 wherein, real-time cell analysis can be performed on a microfluidic chip platform. The new generation of microfluidic chips should include not only bulk assay, but also single cell analysis in order to evaluate and clearly identify the role of cell communication in spreading or deterring of nanotoxicity. The next section briefly discusses the associated challenges in nanotoxicity assessment with conclusion.




Figure 9: Schematic of an ideal microfluidic CoC device for nanotoxicity assessment. The presented CoC can assess toxicity at single cell level and at group of cells. It can compare the microscopic and macroscopic effects and can present a clear role of NP interaction with single cell by blocking other stimulating factors, such as cues from neighbour cells, and with the overall integrative effects produced by NP and the cell cell communication in a population of cells.

4.0. Challenges and conclusion

Looking at the growth of nanotechnology, number of nanomaterials (metallic, metal oxide based, ceramic, carbon based, polymeric, polymer based, biomolecule based, magnetic and composites) are developed along with various sizes makes the matrix of nanomaterials to be tested very huge. Screening of the huge number of nanomaterials at *in vivo* level cannot provide the speed, cost and faces ethical concern. A large number of *in vitro* test are available, and we need to perform more than one type experiment to be sure about the results. In such a condition, we need very sensitive, rapid, cost effective and easy to operate analytical tools in labs. Single

1
2 cell has been shown to be more sensitive towards a smaller change than population of cell in a
3
4 shorter time⁹¹.
5
6

7
8 To analyze single cells, sorting of a single cell from population of cell is necessary. One
9
10 of the most frequently used method to quickly and efficiently sort, count and/or measure the
11
12 characteristics of single cells in large volume (large throughput) is flow-cytometry (FCM).
13
14 However, it requires cells to be tagged with fluorescent probes that may interfere with the natural
15
16 behavior of the cell. A technique which measures cell behavior in its natural state would be ideal.
17
18 Patch clamp and carbon fiber microelectrode based techniques are good for single cell analysis;
19
20 however, require cumbersome and expensive equipment, as well as, a trained professional to
21
22 conduct the experiments. Performing these techniques can be very time consuming and yield a
23
24 low throughput. On the other hand, using a chip based approach to sort and analyze single cells
25
26 out of a population seems to be more cost effective, simpler and can yield a higher throughput
27
28 performance. Microelectrodes on chip integrated with microfluidic control and automation not
29
30 only would make the initial nanotoxicity screening easy, but also would increase the
31
32 participation from various authorities, and encourage the nanotoxicity assessment efforts
33
34 throughout the world. CoC-based assays will provide more dynamic information of cell and
35
36 particle interaction. Currently, not all the labs that work with nanomaterials have the facilities
37
38 and equipment to perform traditional nanotoxicity assays. CoC-based assay can be an initial
39
40 screening point for nanotoxicity.
41
42
43
44
45
46
47

48 **Acknowledgement**


49
50
51 This study was supported by the grant R15ES021079 from the National Institute of
52
53 Health (U.S.A.) and the grant 21328501 from National Science Foundations of China to CZ Li
54
55 and CX Zhang.
56
57
58
59
60

References

1. Consumer Products Inventory, <http://www.nanotechproject.org/cpi>, Accessed 12/03/2013.
2. D. B. Trout and P. A. Schulte, *Toxicology*, 2010, **269**, 128-135.
3. M. Simko and M. O. Mattsson, *Part Fibre Toxicol*, 2010, **7**, 42.
4. C. Buzea, Pacheco, II and K. Robbie, *Biointerphases*, 2007, **2**, MR17-71.
5. W. G. Kreyling, S. Hirn and C. Schleh, *Nat Biotechnol*, 2010, **28**, 1275-1276.
6. T. Hartung, *ALTEX*, 2010, **27**, 87-95.
7. W. H. De Jong and P. J. Borm, *Int J Nanomedicine*, 2008, **3**, 133-149.
8. M. S. Xu, J. Li, H. Iwai, Q. S. Mei, D. Fujita, H. X. Su, H. Z. Chen and N. Hanagata, *Sci Rep-Uk*, 2012, **2**.
9. P. R. Lockman, R. J. Mumper, M. A. Khan and D. D. Allen, *Drug Dev Ind Pharm*, 2002, **28**, 1-13.
10. Nanoparticles for drug delivery to the brain, http://en.wikipedia.org/wiki/Nanoparticles_for_drug_delivery_to_the_brain.
11. G. A. Silva, *Nat Rev Neurosci*, 2006, **7**, 65-74.
12. K. K. Jain, *Clin Chem*, 2007, **53**, 2002-2009.
13. C. Medina, M. J. Santos-Martinez, A. Radomski, O. I. Corrigan and M. W. Radomski, *Br J Pharmacol*, 2007, **150**, 552-558.
14. J. Wang, M. F. Rahman, H. M. Duhart, G. D. Newport, T. A. Patterson, R. C. Murdock, S. M. Hussain, J. J. Schlager and S. F. Ali, *Neurotoxicology*, 2009, **30**, 926-933.
15. G. Oberdorster, Z. Sharp, V. Atudorei, A. Elder, R. Gelein, W. Kreyling and C. Cox, *Inhal Toxicol*, 2004, **16**, 437-445.
16. W. H. Suh, K. S. Suslick, G. D. Stucky and Y. H. Suh, *Prog Neurobiol*, 2009, **87**, 133-170.
17. S. V. Fedorovich, A. V. Alekseenko and T. V. Waseem, *Biochem Soc Trans*, 2010, **38**, 536-538.
18. S. George, S. Pokhrel, T. Xia, B. Gilbert, Z. X. Ji, M. Schowalter, A. Rosenauer, R. Damoiseaux, K. A. Bradley, L. Madler and A. E. Nel, *ACS Nano*, 2010, **4**, 15-29.
19. T. T. Win-Shwe and H. Fujimaki, *Int J Mol Sci*, 2011, **12**, 6267-6280.
20. L. Yin, B. P. Colman, B. M. McGill, J. P. Wright and E. S. Bernhardt, *PLoS One*, 2012, **7**, e47674.
21. A. A. Shvedova, V. E. Kagan and B. Fadeel, *Annu Rev Pharmacol Toxicol*, 2010, **50**, 63-88.
22. A. F. Hubbs, R. R. Mercer, S. A. Benkovic, J. Harkema, K. Sriram, D. Schwegler-Berry, M. P. Goravanahally, T. R. Nurkiewicz, V. Castranova and L. M. Sargent, *Toxicol Pathol*, 2011, **39**, 301-324.
23. NNI Budget, <http://nano.gov/about-nni/what/funding>.
24. J. Howard, The National Institute for Occupational Safety and Health (NIOSH), <http://www.cdc.gov/niosh/enews/enewsV10N3.html>, 10.
25. L. Y. Chou, K. Ming and W. C. Chan, *Chem Soc Rev*, 2011, **40**, 233-245.
26. S. Sohaebuddin, P. Thevenot, D. Baker, J. Eaton and L. Tang, *Particle and Fibre Toxicology*, 2010, **7**, 22.
27. E. Hondroulis, C. Liu and C. Z. Li, *Nanotechnology*, 2010, **21**, 315103.
28. A. Nel, T. Xia, L. Madler and N. Li, *Science*, 2006, **311**, 622-627.
29. K. Donaldson, V. Stone, C. L. Tran, W. Kreyling and P. J. Borm, *Occup Environ Med*, 2004, **61**, 727-728.
30. J. Wang, P. Sun, Y. Bao, J. Liu and L. An, *Toxicology in Vitro*, 2011, **25**, 242-250.
31. D. Napierska, L. C. Thomassen, V. Rabolli, D. Lison, L. Gonzalez, M. Kirsch-Volders, J. A. Martens and P. H. Hoet, *Small*, 2009, **5**, 846-853.
32. X. Huang, X. Teng, D. Chen, F. Tang and J. He, *Biomaterials*, 2010, **31**, 438-448.
33. B. J. Marquis, Z. Liu, K. L. Braun and C. L. Haynes, *Analyst*, 2011, **136**, 3478-3486.
34. N. M. Toriello, E. S. Douglas, N. Thaitrong, S. C. Hsiao, M. B. Francis, C. R. Bertozzi and R. A. Mathies, *Proc Natl Acad Sci U S A*, 2008, **105**, 20173-20178.
35. J. M. Irish, N. Kotecha and G. P. Nolan, *Nat Rev Cancer*, 2006, **6**, 146-155.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
36. T. Graf and M. Stadtfeld, *Cell Stem Cell*, 2008, **3**, 480-483.
37. D. Wang and S. Bodovitz, *Trends Biotechnol*, 2010, **28**, 281-290.
38. J. F. L. Trisha Eustaquio, in *Nanotoxicity*, ed. J. Reineke, Humana Press, 2012, ch. 5, pp. 69-85.
39. J. M. Hillegass, A. Shukla, S. A. Lathrop, M. B. MacPherson, N. K. Fukagawa and B. T. Mossman, *Wiley Interdiscip Rev Nanomed Nanobiotechnol*, 2010, **2**, 219-231.
40. B. J. Marquis, S. A. Love, K. L. Braun and C. L. Haynes, *Analyst*, 2009, **134**, 425-439.
41. C. F. Jones and D. W. Grainger, *Adv Drug Deliv Rev*, 2009, **61**, 438-456.
42. S. M. Poonam Takhar, *Archives of Applied Science Research*, 2011, **3**, 389-403.
43. K. Bhattacharya, M. Davoren, J. Boertz, R. P. Schins, E. Hoffmann and E. Dopp, *Part Fibre Toxicol*, 2009, **6**, 17.
44. H. L. Karlsson, P. Cronholm, J. Gustafsson and L. Moller, *Chem Res Toxicol*, 2008, **21**, 1726-1732.
45. B. Fahmy and S. A. Cormier, *Toxicology in Vitro*, 2009, **23**, 1365-1371.
46. K. Sanders, L. L. Degn, W. R. Mundy, R. M. Zucker, K. Dreher, B. Zhao, J. E. Roberts and W. K. Boyes, *Toxicol Appl Pharmacol*, 2012, **258**, 226-236.
47. I. Pujalte, I. Passagne, B. Brouillaud, M. Treguer, E. Durand, C. Ohayon-Courtes and B. L'Azou, *Part Fibre Toxicol*, 2011, **8**, 10.
48. J. Y. Choi, S. H. Lee, H. B. Na, K. An, T. Hyeon and T. S. Seo, *Bioprocess Biosyst Eng*, 2010, **33**, 21-30.
49. M. Ahamed, M. J. Akhtar, M. A. Siddiqui, J. Ahmad, J. Musarrat, A. A. Al-Khedhairi, M. S. AlSalhi and S. A. Alrokayan, *Toxicology*, 2011, **283**, 101-108.
50. S. J. Soenen, U. Himmelreich, N. Nuytten and M. De Cuyper, *Biomaterials*, 2011, **32**, 195-205.
51. C. C. Huang, R. S. Aronstam, D. R. Chen and Y. W. Huang, *Toxicology in Vitro*, 2010, **24**, 45-55.
52. D. Drescher, G. Orts-Gil, G. Laube, K. Natte, R. W. Veh, W. Osterle and J. Kneipp, *Anal Bioanal Chem*, 2011, **400**, 1367-1373.
53. S. Vankoningsloo, J. P. Piret, C. Saout, F. Noel, J. Mejia, C. C. Zouboulis, J. Delhalle, S. Lucas and O. Toussaint, *Nanotoxicology*, 2010, **4**, 84-97.
54. R. Hamid, Y. Rotshteyn, L. Rabadi, R. Parikh and P. Bullock, *Toxicology in Vitro*, 2004, **18**, 703-710.
55. N. A. Monteiro-Riviere, A. O. Inman and L. W. Zhang, *Toxicol Appl Pharmacol*, 2009, **234**, 222-235.
56. A. Casey, E. Herzog, M. Davoren, F. M. Lyng, H. J. Byrne and G. Chambers, *Carbon*, 2007, **45**, 1425-1432.
57. Y. Chang, S. T. Yang, J. H. Liu, E. Dong, Y. Wang, A. Cao, Y. Liu and H. Wang, *Toxicol Lett*, 2011, **200**, 201-210.
58. J. E. Bae, M. I. Huh, B. K. Ryu, J. Y. Do, S. U. Jin, M. J. Moon, J. C. Jung, Y. Chang, E. Kim, S. G. Chi, G. H. Lee and K. S. Chae, *Biomaterials*, 2011, **32**, 9401-9414.
59. L. Wang, S. Luanpitpong, V. Castranova, W. Tse, Y. Lu, V. Pongrakhananon and Y. Rojanasakul, *Nano Lett*, 2011, **11**, 2796-2803.
60. Y. Pan, A. Leifert, D. Ruau, S. Neuss, J. Bornemann, G. Schmid, W. Brandau, U. Simon and W. Jahnen-Dechent, *Small*, 2009, **5**, 2067-2076.
61. S. Q. Li, R. R. Zhu, H. Zhu, M. Xue, X. Y. Sun, S. D. Yao and S. L. Wang, *Food Chem Toxicol*, 2008, **46**, 3626-3631.
62. M. J. Akhtar, M. Ahamed, M. Fareed, S. A. Alrokayan and S. Kumar, *J Toxicol Sci*, 2012, **37**, 139-148.
63. C. C. Ho, Y. H. Luo, T. H. Chuang, C. S. Yang, Y. C. Ling and P. Lin, *Toxicology*, 2013, **308**, 1-9.
64. B. Ekstrand-Hammarstrom, C. M. Akfur, P. O. Andersson, C. Lejon, L. Osterlund and A. Bucht, *Nanotoxicology*, 2012, **6**, 623-634.
65. W. S. Cho, R. Duffin, C. A. Poland, A. Duschl, G. J. Oostingh, W. MacNee, M. Bradley, I. L. Megson and K. Donaldson, *Nanotoxicology*, 2012, **6**, 22-35.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
66. Y. Morimoto, A. Ogami, M. Todoroki, M. Yamamoto, M. Murakami, M. Hirohashi, T. Oyabu, T. Myojo, K. Nishi, C. Kadoya, S. Yamasaki, H. Nagatomo, K. Fujita, S. Endoh, K. Uchida, K. Yamamoto, N. Kobayashi, J. Nakanishi and I. Tanaka, *Nanotoxicology*, 2010, **4**, 161-176.
67. J. Cancino, I. M. Paino, K. C. Micocci, H. S. Selistre-de-Araujo and V. Zucolotto, *Toxicol Lett*, 2013, **219**, 18-25.
68. V. Diana, P. Bossolasco, D. Moscatelli, V. Silani and L. Cova, *PLoS One*, 2013, **8**, e78435.
69. J. M. Hillegass, A. Shukla, S. A. Lathrop, M. B. MacPherson, N. K. Fukagawa and B. T. Mossman, *Wires Nanomed Nanobi*, 2010, **2**, 219-231.
70. X. Zhu, E. Hondroulis, W. Liu and C. Z. Li, *Small*, 2013, **9**, 1821-1830.
71. Y. Wu, T. Yu, T. A. Gilbertson, A. Zhou, H. Xu and K. T. Nguyen, *PLoS One*, 2012, **7**, e36885.
72. S. A. Love and C. L. Haynes, *Anal Bioanal Chem*, 2010, **398**, 677-688.
73. M. A. Maurer-Jones, Y. S. Lin and C. L. Haynes, *ACS Nano*, 2010, **4**, 3363-3373.
74. B. J. Marquis, M. A. Maurer-Jones, K. L. Braun and C. L. Haynes, *Analyst*, 2009, **134**, 2293-2300.
75. J. Blechinger, A. T. Bauer, A. A. Torrano, C. Gorzelanny, C. Brauchle and S. W. Schneider, *Small*, 2013, **9**, 3970-3980.
76. L. R. F. A. J. Bard, *Electrochemical Methods: Fundamentals and Applications*, John Wiley & Sons: New York 2001, 2001.
77. B. J. Marquis, A. D. McFarland, K. L. Braun and C. L. Haynes, *Anal Chem*, 2008, **80**, 3431-3437.
78. S. A. Love, Z. Liu and C. L. Haynes, *Analyst*, 2012, **137**, 3004-3010.
79. P. Shah, X. Zhu, C. Chen, Y. Hu and C.-Z. Li, *Biomedical Microdevices*, 2013, 1-7.
80. G. Velve-Casquillas, M. Le Berre, M. Piel and P. T. Tran, *Nano Today*, 2010, **5**, 28-47.
81. X. Zheng, J. Tian, L. Weng, L. Wu, Q. Jin, J. Zhao and L. Wang, *Nanotechnology*, 2012, **23**, 055102.
82. M. Hosokawa, T. Hayashi, T. Mori, T. Yoshino, S. Nakasono and T. Matsunaga, *Anal Chem*, 2011, **83**, 3648-3654.
83. T. H. Kim, S. R. Kang, B. K. Oh and J. W. Choi, *Sensor Lett*, 2011, **9**, 861-865.
84. D. Kim, Y. S. Lin and C. L. Haynes, *Anal Chem*, 2011, **83**, 8377-8382.
85. F. A. Alexander, Jr., E. G. Huey, D. T. Price and S. Bhansali, *Analyst*, 2012, **137**, 5823-5828.
86. K. Luongo, A. Holton, A. Kaushik, P. Spence, B. Ng, R. Deschenes, S. Sundaram and S. Bhansali, *Biomicrofluidics*, 2013, **7**, 034108.
87. Y. C. Tung, A. Y. Hsiao, S. G. Allen, Y. S. Torisawa, M. Ho and S. Takayama, *Analyst*, 2011, **136**, 473-478.
88. S. Poenick, H. G. Jahnke, M. Eichler, S. Frost, H. Lilie and A. A. Robitzki, *Biosensors & Bioelectronics*, 2014, **53**, 370-376.
89. D. Huh, B. D. Matthews, A. Mammoto, M. Montoya-Zavala, H. Y. Hsin and D. E. Ingber, *Science*, 2010, **328**, 1662-1668.
90. A. Albanese, A. K. Lam, E. A. Sykes, J. V. Rocheleau and W. C. W. Chan, *Nat Commun*, 2013, **4**, 3718.
91. F. Asphahani, K. Wang, M. Thein, O. Veisoh, S. Yung, J. Xu and M. Zhang, *Phys Biol*, 2011, **8**, 015006.



A microfluidic CoC system for nanotoxicity assessment at single and multiple cells which can measure and compare the microscopic and macroscopic effects of nanoparticles interaction with cells, without interference from neighbor cells' cues and also overall integrative effects produced by nanoparticles and cell-cell communication.